Identification of factors which induce radiation injury, and establishment of tailor-made irradiation based upon these factors.
| Project/Area Number |
24592179
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Chiba Cancer Center (Research Institute) |
|---|
Principal Investigator |
IUCHI TOSHIHIKO 千葉県がんセンター(研究所), 脳神経外科, 部長 (80370881)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 脳腫瘍学 / 放射線脳壊死 / 神経膠芽腫 / テーラーメイド治療 / 放射線脳障害 / 分子 / 神経膠腫 / 放射線治療 / 脳白質障害 / 放射線壊死 / 遺伝子変異解析 / 遺伝子メチル化解析 / 遺伝子発現 |
|---|
| Outline of Final Research Achievements |
The change in copy number, but not mutation, of PDGFRA was associated with radiation necrosis. We could not find other molecules which showed significant correlation with radiation necrosis, from the analyses by array-CGH, cDNA array, and next generation sequencing. On the other hand, the methylation status of MGMT gene promoter was significant risk factor for radiation injury, and tumors with methylated MGMT gene promoter had higher risk for necrosis. Tailor-made setting of irradiation doses (high-dose for MGMT unmethylated cases, and moderate-dose for methylated ones) had revealed that decrease of irradiation dose had contributed to prevent radiation injury, while keeping the same survival benefit of irradiation. These findings indicated the feasibility of tailor-made setting of treatment doses based upon the methylation status of MGMT gene promoter.
|
Report
(4 results)
Research Products
(30 results)
-
-
[Journal Article] Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations.2015
Author(s)
Iuchi T, Shingyoji M, Itakura M, Yokoi S, Moriya Y, Tamura H, Yoshida Y, Ashinuma H, Kawasaki K, Hasegawa Y, Sakaida T, Iizasa T.
-
Journal Title
Int J Clin Oncol.
Volume: 未定
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.2013
Author(s)
T. Iuchi, M. Shingyoji, T. Sakaida, K Hatano, O. Nagano, M. Itakura, H. Kageyama, S. Yokoi, Y. Hasegawa, K. Kawasaki, T. Iizasa
-
Journal Title
Lung Cancer.
Volume: 82
Issue: 2
Pages: 282-287
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma.2013
Author(s)
Yamaki T, Suenaga Y, Iuchi T, Alagu J, Takatori A, Itami M, Araki A, Ohira M, Inoue M, Kageyama H, Yokoi S, Saeki N, Nakagawara A.
-
Journal Title
Sci Rep.
Volume: 3
Issue: 1
Pages: 1160-1160
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
[Presentation] EGFR-TKI 時代における非小細胞肺癌脳転移治療～非照射TKI 単独治療の効果と安全性～2014
Author(s)
井内俊彦, 新行内雅人, 板倉明司, 横井左奈, 守屋康充, 吉田泰司, 芦沼宏典, 松井由紀子, 田村創, 石橋文博, 長谷川祐三, 川﨑宏一郎, 堺田司, 飯笹俊彦
Organizer
日本癌治療学会
Place of Presentation
横浜
Year and Date
2014-08-28 – 2014-08-30
Related Report
Invited
-
-
-
-
-
-
[Presentation] Methionine-uptake, delivered dose and control of the lesion in the treatment of malignant astrocytomas.2013
Author(s)
T Iuchi, K Hatano, Y Uchino, T Kodama, N Toyama, T Kawachi, Y Hasegawa, K Kawasaki, T Sakaida.
Organizer
2nd. ESTRO (European Society for Therapeutic Radiation Oncology) Forum
Place of Presentation
Geneva, Switzerland
Related Report
-
-
-
[Presentation] The incidence and clinical feature of brain metastasis from non-small cell lung cancer, and their associations with EGFR mutation.2013
Author(s)
T. Iuchi, M. Shingyoji, T. Sakaida, M. Itakura, H. Kageyama, S. Yokoi, Y. Hasegawa, K. Kawasaki, T. Iizasa.
Organizer
17th. ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress
Place of Presentation
Amsterdam, Hollan
Related Report
-
-
-
-
-
-
